DE69943089D1 - Methode zur behandlung von staphylokokkeninfektionen - Google Patents

Methode zur behandlung von staphylokokkeninfektionen

Info

Publication number
DE69943089D1
DE69943089D1 DE69943089T DE69943089T DE69943089D1 DE 69943089 D1 DE69943089 D1 DE 69943089D1 DE 69943089 T DE69943089 T DE 69943089T DE 69943089 T DE69943089 T DE 69943089T DE 69943089 D1 DE69943089 D1 DE 69943089D1
Authority
DE
Germany
Prior art keywords
staphylokocksinfections
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69943089T
Other languages
English (en)
Inventor
Michael M Climo
Gordon L Archer
Beth P Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AMBI Inc
Original Assignee
AMBI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AMBI Inc filed Critical AMBI Inc
Application granted granted Critical
Publication of DE69943089D1 publication Critical patent/DE69943089D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)
DE69943089T 1998-08-27 1999-08-27 Methode zur behandlung von staphylokokkeninfektionen Expired - Lifetime DE69943089D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/140,732 US6028051A (en) 1997-07-23 1998-08-27 Method for the treatment of staphylococcal disease
PCT/US1999/020396 WO2000012049A2 (en) 1998-08-27 1999-08-27 A method for the treatment of staphylococcal disease

Publications (1)

Publication Number Publication Date
DE69943089D1 true DE69943089D1 (de) 2011-02-10

Family

ID=22492556

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69943089T Expired - Lifetime DE69943089D1 (de) 1998-08-27 1999-08-27 Methode zur behandlung von staphylokokkeninfektionen

Country Status (12)

Country Link
US (1) US6028051A (de)
EP (1) EP1107722B1 (de)
JP (1) JP2002523437A (de)
AR (1) AR023645A1 (de)
AT (1) ATE493145T1 (de)
AU (1) AU5811199A (de)
CA (1) CA2341699A1 (de)
DE (1) DE69943089D1 (de)
IL (1) IL141648A0 (de)
NO (1) NO20010953L (de)
WO (1) WO2000012049A2 (de)
ZA (1) ZA995444B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091332B1 (en) 1998-06-22 2006-08-15 University Of Vermont Treatment of staphylococcus infections
US6875903B2 (en) * 1998-06-22 2005-04-05 University Of Vermont Treatment of Staphylococcus infections
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US20030211995A1 (en) * 2001-12-21 2003-11-13 Kokai-Kun John Fitzgerald Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
EP1465990B1 (de) * 2001-12-21 2011-07-13 Biosynexus Incorporated Gestutzes lysostaphin-molekül mit verbesserter staphylolytischer wirkung
US6759881B2 (en) * 2002-03-22 2004-07-06 Rambus Inc. System with phase jumping locked loop circuit
US7572439B2 (en) * 2002-03-26 2009-08-11 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
EP1494706A4 (de) * 2002-03-26 2006-10-25 Biosynexus Inc Antimikrobielle polymerkonjugate
EA200500804A1 (ru) * 2002-12-10 2005-12-29 Биосинексус Инкорпорейтед Топические противоинфекционные композиции
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
US20070190542A1 (en) * 2005-10-03 2007-08-16 Ling Xinsheng S Hybridization assisted nanopore sequencing
WO2008105826A2 (en) * 2006-09-05 2008-09-04 Biosynexus Incorporated Compositions compromising lysostaphin variants and methods of using the same
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009150171A1 (en) * 2008-06-10 2009-12-17 Profos Ag Method of treatment of inflammatory diseases
CA2948864C (en) 2014-05-14 2023-10-17 Karl E. Griswold Deimmunized lysostaphin and methods of use
CN109819650A (zh) 2017-09-25 2019-05-28 春布里泽·格奥尔基·格奥尔基耶维奇 具有抗病毒和抗细菌活性的热稳定组合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067099A (en) * 1955-09-16 1962-12-04 Lilly Co Eli Vancomycin and method for its preparation
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases

Also Published As

Publication number Publication date
CA2341699A1 (en) 2000-03-09
NO20010953D0 (no) 2001-02-26
AR023645A1 (es) 2002-09-04
EP1107722B1 (de) 2010-12-29
JP2002523437A (ja) 2002-07-30
IL141648A0 (en) 2002-03-10
ATE493145T1 (de) 2011-01-15
ZA995444B (en) 2000-07-10
NO20010953L (no) 2001-03-21
EP1107722A4 (de) 2006-05-17
WO2000012049A2 (en) 2000-03-09
EP1107722A2 (de) 2001-06-20
AU5811199A (en) 2000-03-21
US6028051A (en) 2000-02-22
WO2000012049A3 (en) 2000-05-25

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69810584T2 (de) Verfahren und Methode zur Behandlung von Abfällen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69806579T2 (de) Anlage zur behandlung von nahrungsmitteln
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
DE60035326D1 (de) Verfahren zur Behandlung von Abwasser
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69834578D1 (de) Verfahren zur behandlung von zementaufschlämmungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
DE69922786D1 (de) Methode zur behandlung der chronischen obstruktiven bronchopneumopathie
DE60023555D1 (de) Verfahren zur behandlung von gewebe
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen